• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Psychedelic Invest

Investing in Psychedelics

  • Home
  • News
    • Analysis
    • Interviews
    • Press
  • Index
  • Resources
    • Psychedelic Investors
    • Psychedelic Stocks
    • Psychedelic Law Firms
    • Events
    • Jobs
  • Invest

Entheon Biomedical to Begin Trading on the Frankfurt Exchange

Quick Take:

  • Entheon Biomedical Corp. shares have commenced trading on the Frankfurt Stock Exchange under the symbol “1XU1”
  • The Company’s shares will also continue to trade on the Canadian Securities Exchange under the symbol “ENBI“.

Vancouver, British Columbia–(Newsfile Corp. – November 26, 2020) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its shares have commenced trading on the Frankfurt Stock Exchange under the symbol “1XU1”. 

The Frankfurt Stock Exchange is the world’s tenth largest organized exchange-trading market in terms of turnover and dealings in securities. Over 3,000 international companies are listed on the Frankfurt Exchange. 

“We are pleased to have Entheon listed on the FSE in addition to the CSE. This presence will expand accessibility to a larger, more global community of potential institutional and retail investors, with the potential of expanding our shareholder base while increasing Entheon’s liquidity. By trading on the FSE, the Company has extended its trading window by an additional six hours.”

– Timothy Ko, CEO of Entheon.

The Company’s common shares will continue to trade on the Canadian Securities Exchange under the symbol “ENBI“.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products“) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada. 

Original Press Release

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Facebook
  • LinkedIn
  • RSS
  • Twitter

The Next Wave
of BioTech

Subscribe to our newsletter to get the latest business and investing news about the burgeoning psychedelics industry.

Recent Posts

  • Mydecine Innovations Group Files Application to list to the NASDAQ January 27, 2021
  • Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US January 26, 2021
  • Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression January 25, 2021
  • PharmaTher Signs License Agreement for Patented Ketamine Treatment January 22, 2021
  • January, 2021 Update: Psychedelic Index Adds 7 New Companies January 22, 2021
Psychedelics by TradingView

Interview Series

journey colab psychedelics
fluence psychedelic therapy
CaaMTech Davis Wuolle

Footer

Psychedelic Investor

Psychedelics are set to disrupt the multi billion dollar alcohol, tobacco, pharmaceutical, and health & wellness industries.

There is an enormous opportunity for those early investors who are able to look past the historical negative stigma associated with many psychedelics.

Psychedelic Invest is a resource for those looking to invest in the psychedelic industry.

Quick Links

  • About
  • Contact
  • Terms of Use
  • Psychedelic Stock Index
  • Careers

Subscribe

Copyright © 2021 · Psychedelic Invest